Home Cart Sign in  
Chemical Structure| 20086-06-0 Chemical Structure| 20086-06-0

Structure of Diosbulbin B
CAS No.: 20086-06-0

Chemical Structure| 20086-06-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Diosbulbin B, a natural product isolated and purified from the roots of Dioscorea bulbifera, has potential anti-tumor effects which may be related to influencing the immune system for the first time.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Diosbulbin B

CAS No. :20086-06-0
Formula : C19H20O6
M.W : 344.36
SMILES Code : O=C1O[C@]2([H])[C@@]3([H])[C@](C[C@@]4([H])OC([C@]3([H])C4)=O)([H])[C@@]5(C)[C@]1(C2)O[C@@H](C6=COC=C6)C5
MDL No. :MFCD16660673

Safety of Diosbulbin B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BGC823/CDDP cells 12.5 μM 0 h, 24 h, 48 h, 72 h Low-dose DB significantly induced apoptotic cell death in cisplatin-treated CR-GC cells and triggered NLRP3-mediated pyroptosis. Cell Biosci. 2021 Feb 12;11(1):38
SGC7901/CDDP cells 12.5 μM 0 h, 24 h, 48 h, 72 h Low-dose DB significantly induced apoptotic cell death in cisplatin-treated CR-GC cells and triggered NLRP3-mediated pyroptosis. Cell Biosci. 2021 Feb 12;11(1):38
mouse liver microsomes 200 μM 30 minutes To study the metabolic activation of Diosbulbin B and its covalent binding to proteins Toxins (Basel). 2017 Aug 14;9(8):249
HGC-27 cells 0, 3.125, 6.25, 12.5, 25, 50, or 100 µM 48 hours To detect the IC50 of Diosbulbin B in HGC-27 cells, results showed that circHECTD1 deficiency enhanced the sensitivity to Diosbulbin B. Cancer Cell Int. 2021 May 17;21(1):264
AGS cells 0, 3.125, 6.25, 12.5, 25, 50, or 100 µM 48 hours To detect the IC50 of Diosbulbin B in AGS cells, results showed that circHECTD1 deficiency enhanced the sensitivity to Diosbulbin B. Cancer Cell Int. 2021 May 17;21(1):264
L-02 hepatocytes 50, 100, 200 µM 48 hours To investigate the toxicity of DB on L-02 hepatocytes and its mechanism. Results showed that DB significantly decreased cell viability, induced concentration-dependent apoptosis and autophagy, increased the activities of caspase-3, caspase-9, ALT, and AST, and caused excessive leakage of LDH. Front Pharmacol. 2019 Jun 19;10:676
Primary rat hepatocytes 100 μM 0 h, 6 h, 12 h, 18 h and 24 h To evaluate the effects of high-dose DB on hepatocyte proliferation and apoptosis, results showed that high-dose DB inhibited proliferation and induced apoptosis, which were reversed by ASP co-treatment. Bioengineered. 2021 Dec;12(1):3516-3524

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Xenograft tumor-bearing model 12.5 μM 30 days Low-dose DB enhanced the inhibitory effects of cisplatin on CR-GC cells, reducing tumor volume and weight. Cell Biosci. 2021 Feb 12;11(1):38
Mice Hepatotoxicity model Intraperitoneal injection 75, 150, 200 mg/kg Single dose, liver harvested 12 hours post administration To study the hepatotoxicity of Diosbulbin B in vivo and its covalent binding to proteins Toxins (Basel). 2017 Aug 14;9(8):249
ICR male mice Pulmonary toxicity model Oral gavage 10, 30, 60 mg/kg 4 consecutive weeks To study the toxic effects of Diosbulbin B on mouse lungs and its mechanism. Results showed that DIOB induced lung toxicity by increasing plasma levels of long-chain free fatty acids and inflammation-related endogenous metabolites, and by inhibiting fatty acid β-oxidation, partial glycolysis, and the TCA cycle. Toxicol Res (Camb). 2021 Mar 23;10(2):272-276

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.90mL

0.58mL

0.29mL

14.52mL

2.90mL

1.45mL

29.04mL

5.81mL

2.90mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories